AMP-SCZ.png

AMP-SCZ

Restricted Access | Catalogue record last updated: 2026/06/18

The Accelerating Medicines Partnership (AMP) program is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), pharmaceutical and life science companies, non-profits and other organisations. It is managed by the Foundation for the National Institutes of Health (FNIH). The aim of the AMP program is to improve our understanding of disease pathways and identify new and better targets for treatment. The AMP program consists of two studies- an Observational Study and a Proof of Principle (PoP) Clinical Trial for MT1988. The Observational Study, launched in September 2020, was designed to identify biomarkers and clinical outcome measures that can predict the effectiveness of pharmacological treatments in individuals at clinical high risk for psychosis (CHR).


Scientific field(s): Psychiatry

For the Observational Study:
Data collected include biomarker measures (imaging, EEG, event-related potentials, fluid-based biomarkers), cognitive assessments, speech sampling, digital assessments.

For the Proof of Principle Clinical Trial:
The trial evaluates short-term clinical, biomarker, cognitive and digital measures collected across screening, baseline, treatment and follow-up.
Participants complete interviews and questionnaires, biospecimen samples are collected, as well as several other assessments: clinical assessments, EEG assessments, cognitive assessments and digital assessments.

Data processing level: Processed, Aggregated
Study design: Longitudinal
Method(s): Sample collection, Imaging, Physical measurements

All screenings, biomarker, imaging and clinical assessments are completed at the recruitment centers.
For the Observational Study: clinical assessments are collected monthly for the first year, then at 18 and 24 months and at the point of conversion to psychosis.
Unbiased machine language and AI approaches are used to derive algorithms that predict clinical endpoints.

For the Proof of Principle Clinical Trial: assessments are conducted at baseline and at selected treatment timepoints. Digital assessments will be conducted continuously from baseline through the end of treatment.

Condition(s)/Disease(s): Schizophrenia
Associated ressources:
  • 10.1093/schizbullopen/sgaf012: Addington, J. et al. Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program. Schizophr. Bull. Open 6, sgaf012 (2025).
Catalogue record last updated: June 18, 2026, midnight